StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) stock

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3067% below fair value
$1.61+0.12 (+8.05%)

Close on Nov 17, 2026Market cap $3.77MP/E –Yield –

Xenetic Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Xenetic Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -81.0%. For fiscal 2025 it was -95.2%, against -168.2% the year before. The highest annual figure on record is -47.1% in fiscal 2017.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-95.2%+72.9
FY2024Dec 31, 2024-168.2%+9.6
FY2023Dec 31, 2023-177.8%+215.8
FY2022Dec 31, 2022-393.6%+101.5
FY2021Dec 31, 2021-495.1%+2694.7
FY2020Dec 31, 2020-3189.8%+72321.9
FY2019Dec 31, 2019-75511.7%−75464.7
FY2017Dec 31, 2017-47.1%+1534.0
FY2016Dec 31, 2016-1581.0%−719.7
FY2013Dec 31, 2013-861.3%+1299.5
FY2012Dec 31, 2012-2160.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-147.1%−24.3
Q1 FY2026Mar 31, 2026-62.2%+96.6
Q4 FY2025Dec 31, 2025-81.3%+88.1
Q3 FY2025Sep 30, 2025-53.0%+28.3
Q2 FY2025Jun 30, 2025-122.8%+61.3
Q1 FY2025Mar 31, 2025-158.9%+89.5
Q4 FY2024Dec 31, 2024-169.4%+17.5
Q3 FY2024Sep 30, 2024-81.3%+106.3
Q2 FY2024Jun 30, 2024-184.1%−0.1
Q1 FY2024Mar 31, 2024-248.3%−97.3
Q4 FY2023Dec 31, 2023-186.9%+458.0
Q3 FY2023Sep 30, 2023-187.6%+228.8
Q2 FY2023Jun 30, 2023-184.1%+379.4
Q1 FY2023Mar 31, 2023-151.1%+242.9
Q2 FY2022Jun 30, 2022-644.8%−252.7
Q1 FY2022Mar 31, 2022-416.4%+299.6
Q4 FY2021Dec 31, 2021-563.4%+242.7
Q3 FY2021Sep 30, 2021-394.0%+8666.7
Q2 FY2021Jun 30, 2021-392.1%+477.9
Q1 FY2021Mar 31, 2021-716.0%+1452.8
Q4 FY2020Dec 31, 2020-806.2%+6429.6
Q3 FY2020Sep 30, 2020-9060.7%−9119.8
Q2 FY2020Jun 30, 2020-870.0%+1765.9
Q1 FY2020Mar 31, 2020-2168.8%−2166.7
Q4 FY2019Dec 31, 2019-7235.8%–
Q4 FY2017Dec 31, 201759.1%–
Q3 FY2017Sep 30, 2017-2635.9%–
Q4 FY2016Dec 31, 2016-2.1%–

More Xenetic Biosciences figures

See a number that looks wrong?